Evidence map›Paper›PMID 41206933›Full record

ArticleNeuro-oncology2026

Reliable cognitive changes the first year following guideline-based treatment of isocitrate dehydrogenase mutated gliomas: A longitudinal multicenter study.

Isabelle Rydén, Francesco Latini, Åsa Alberius Munkhammar, Per Hellström, Alice Neimantaite, Andrew Lycett, Dima Harba, Louise Carstam, Malin Blomstrand, Maria Zetterling and 2 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuro-oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Isabelle RydénDepartment of Clinical Neuroscience, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg (I.R., P.H., A.N., A.L., D.H., L.C., A.S., A.S.J.).ORCID 0000-0002-2384-9248
Francesco LatiniSection of Neurosurgery, Department of Neuroscience, Uppsala University, Uppsala (F.L.).ORCID 0000-0002-4702-526X
Åsa Alberius MunkhammarRehabilitation and Pain Centre, Uppsala University Hospital, Uppsala (Å.A.M.).
Per HellströmDepartment of Clinical Neuroscience, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg (I.R., P.H., A.N., A.L., D.H., L.C., A.S., A.S.J.).ORCID 0000-0001-9803-7271
Alice NeimantaiteDepartment of Clinical Neuroscience, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg (I.R., P.H., A.N., A.L., D.H., L.C., A.S., A.S.J.).ORCID 0009-0004-0293-6707
Andrew LycettDepartment of Clinical Neuroscience, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg (I.R., P.H., A.N., A.L., D.H., L.C., A.S., A.S.J.).
Dima HarbaDepartment of Clinical Neuroscience, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg (I.R., P.H., A.N., A.L., D.H., L.C., A.S., A.S.J.).ORCID 0009-0009-2572-6645
Louise CarstamDepartment of Clinical Neuroscience, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg (I.R., P.H., A.N., A.L., D.H., L.C., A.S., A.S.J.).ORCID 0000-0001-6597-2570
Malin BlomstrandDepartment of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg (M.B.).ORCID 0009-0003-5989-0001
Maria ZetterlingSection of Neurosurgery, Department of Neuroscience, Uppsala University, Uppsala (F.L.).ORCID 0000-0003-4590-7063
Anja SmitsDepartment of Clinical Neuroscience, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg (I.R., P.H., A.N., A.L., D.H., L.C., A.S., A.S.J.).ORCID 0000-0003-4171-2672
Asgeir S JakolaDepartment of Clinical Neuroscience, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg (I.R., P.H., A.N., A.L., D.H., L.C., A.S., A.S.J.).ORCID 0000-0002-2860-9331

Funding

Amlövs stiftelseAnna-Lisa and Bror Björnssons stiftelseGöteborg Foundation for Neurological ResearchJubileumsklinikens CancerfondSwedish government and the county councils ALFGBG-1006089Swedish government and the county councils ALFGBG-965622Swedish government and the county councils ALFGBG-983875Swedish Neuropsychological SocietySwedish Research Council 2017-00944The Swedish Society of Medicine SLS-985028
6 · The paper itself

Abstract

backgroundManagement of isocitrate dehydrogenase (IDH) mutated gliomas is multidisciplinary and current guidelines support early multimodal treatment. The effects of this treatment approach on cognition are less studied. We aimed to study changes in cognitive functioning the first year following treatment in these patients and explore predictors of cognitive deterioration.

methodsPatients with a first-time diagnosis of IDH mutated glioma were neuropsychologically assessed before and one year after surgery. Results were compared to published norms, and impairment defined as z <-1.645. Matched controls were assessed at corresponding times, and reliable change indices (RCIs) were calculated to account for practice effects. Logistic regression models investigated predictors for cognitive declines. Tumor locations for declined versus non-declined patients were visualized using heatmaps.

resultsOf the 127 included patients, 104 underwent multi-modal treatment. Pre-operative impairments ranged from 3% to 24%, depending on the specific test. Cognitive declines according to RCI domains were largest in tests of executive functioning (24%), learning/memory (23%), and language (21%). Tests of inhibition/flexibility (32%), naming speed (29%), verbal memory (28%), object naming (28%), and verbal fluency (22%) showed the largest proportions of declines. Regression models revealed that older age and chemoradiotherapy predicted declines in specific domains as well as in individual tests (P < 0.05).

conclusionsSignificant changes occurred in several cognitive domains after guideline-based treatment. Older age and chemoradiotherapy increased the risk of cognitive declines one year after surgery, but to which extent the deficits are persistent or progressing remains unknown.

Indexed as

Brain NeoplasmsCognitionCognitive DysfunctionGliomaIsocitrate DehydrogenaseMutationAdultAgedCombined Modality TherapyFemaleFollow-Up StudiesHumansLongitudinal StudiesMaleMiddle AgedNeuropsychological TestsIsocitrate DehydrogenasecognitionIDH mutationlow-grade gliomaneurosurgeryreliable change index

Identifiers

PMID41206933
PMCPMC13070499

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.